Wednesday November 25 2009 | Biotechnology feed | All feeds
|
|
Wednesday November 25 2009 | Biotechnology feed | All feeds
|
|
|
CB1 antagonists reduce survival rates following experimental myocardial infarction The cloning of CB1 and CB2 cannabinoid receptor subtypes at the beginning of the last decade, and the subsequent development of selective tools has advanced the concept of therapeutically targeting the cannabinoid receptors. A wide range of clinical conditions are indicated, and since CB1 receptors are extensively expressed in the brain, many diseases suggested to benefit from cannabinoid ligands are those with a central components. Consequently CB1 receptor antagonists have been suggested to improve Parkinson's disease by regulating motor centers including the basal ganglia and to reduce food intake by acting at reward centers. Cannabinoid receptors are widespread and a host of physiological functions have been attributed to endogenous cannabinoids including the control of cardiovascular function being strong vasodilators as well as playing a role in the response to hemorrhage. The risk of CB1 antagonists carrying serious cardiovascular side-effects must therefore be closely investigated. Research emerging from the University of Wurzburg is important in this respect. In a model of myocardial infarction, the CB1 antagonist, SR141716A was found to prevent associated reduction mean arterial pressure. However, tachycardia and mortality were both doubled. This suggests that the safety of CB1 antagonists should be carefully monitored in patients at risk of myocardial infarction. Projects such as these are overviewed in full DiscoveryDossiers. DiscoveryDossiers ~ TherapeuticsAdvances ~ PharmaceuticalSolutions ~ LeadDiscovery ~ Purchase DiscoveryDossiersLeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider. |
|
|
